Ganga Pharmaceuticals Limited
CIN: L99999MH1989PLC053392
Regd. Office: Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar - 401305
Phone: 9834613142 |Website: www.ayurvedganga.com. | Email: ayurvedganga@gmail.com.

November 02, 2026

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400 001
Scrip Code: 539680

Sub: Intimation pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – Outcome of the Board Meeting – Financial Results

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of the SEBI Listing Regulations, please take note that the Board of Directors of the Company has, at its Meeting held today i.e., November 02, 2026, considered and approved, inter-alia, the Un-audited Financial Results of the Company for the half year ended September 30, 2026 along with the Limited Review Report of the Statutory Auditors thereon.

The said results along with the Limited Review Report is annexed herewith.

The above information is also available on the website of the Company i.e., www.ayurvedganga.com.

The Board Meeting commenced at 03:40 p.m. and concluded at 4.10 p.m.

Kindly take the same on records.

Thanking You,

Yours faithfully,
For Ganga Pharmaceuticals Limited

SHARMA BHARAT B
Digitally signed by SHARMA BHARAT B
Date: 2026.11.02 16:15:24 +05'30'

Bharat Sharma
Managing Director
DIN: 00077026
Email Id: bharat.sharma@gangapharma.in.

Encl: As above

BANKA & BANKA
CHARTERED ACCOUNTANTS

INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE HALF YEAR ENDED 30.09.2026

(Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended)

To.
The Board of Director
Ganga Pharmaceuticals Ltd.

We have reviewed the accompanying Statement of unaudited financial results of Ganga Pharmaceuticals Ltd ("the Company") for the half year ended 30 September 2026 ("the Statement"). This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries made of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with the applicable Indian Accounting Standards and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Yours Faithfully,

For BANKA & BANKA
CHARTERED ACCOUNTANTS
ICAI FIRM REG. NO.: 100979W

BANKA & BANKA ★ MUMBAI ★ CHARTERED ACCOUNTANTS

(Pradeep P. Banka)
Partner
Membership No.: - 038800

UDIN: 26038800TMTOBL4304

Mumbai :- 02/11/2026

CORRESPONDENCE OFFICE :
3rd Floor, Rajan House, Dr. Annie Besant Road, Prabhadevi, Opp. Century Bazar, Mumbai - 400025. Maharashtra

Shah Trade Centre, 3rd Floor, Above State Bank of India, Rani Sati Marg, Off. W. E. Highway, Malad (E), Mumbai - 400097.

Off: 022 40984545
Fax: 022 40984546

info@bankabanka.com
www.bankabanka.com

GANGA PHARMACEUTICALS LIMITED
CIN: L99999MH1989PLC053392
REGISTERED OFFICE ADDRESS : GANGATAT, DHANVANTARI MARG, GOPCHAR PADA, VIRAR (EAST)-401 305.
Phone No.9967840111 Email id: ayurvedaganga@gmail.com , Website: www.ayurvedganga.com

Statement of Un-Audited Financial Results for the Half and Year ended 30th September 2026.

Rs.in Lakhs

Sr. No	Particulars	Figures for the half year ended on			Financial year ended on	Financial year ended on
		30-09-2026	31-03-2026	30-09-2025	31-03-2026	31-03-2025
		(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	(Audited)
1	**INCOME FROM OPERATIONS**					
	(a) Revenue from operations	141.63	146.14	136.65	282.79	263.74
	(b) Other Income	13.64	13.11	14.80	27.91	43.59
	Total Income	**155.27**	**151.45**	**146.91**	**310.70**	**307.33**
2	*Expenses:*					
	(a) Cost of Materials consumed	80.42	49.14	70.04	119.18	120.55
	(b) Purchase of stock in trade					
	(c) Change in inventories of finished goods & packing Material	(7.72)	18.53	(7.37)	11.16	0.93
	(d) Employee Benefit Expenses	32.72	26.86	31.97	58.83	57.71
	(e) Finance Cost	5.53	6.66	6.64	13.30	17.85
	(f) Depreciation and Amortization Expense	2.81	3.05	2.54	5.59	4.65
	(g) Other Administrative Expenses	38.99	45.42	44.29	89.71	96.18
	Total Expenses	**152.76**	**148.10**	**144.16**	**297.77**	**297.86**
3	**Profit/(Loss) before Tax (1-2)**	2.52	9.58	3.35	12.93	9.47
4	**Tax Expenses**					
	(a) Current Tax	0.91	2.21	0.82	3.03	1.48
	(b) Deffered Tax	(0.26)	(0.30)	0.05	(0.25)	0.09
5	Net Profit / (Loss) for the period (3-4)	**1.86**	**2.48**	**5.50**	**10.15**	**7.90**
6	**Other Comprehensive Income**					
7	Paid - Up equity share capital (Equity Share of Rs. 10/- each)	591.15	591.15	591.15	591.15	483.65
8	Earning per equity share (Rs.)					
	(1) Basic	0.03	0.13	0.04	0.17	0.16
	(2) Diluted	0.03	0.13	0.04	0.17	0.12

For and on behalf of the Board of Directors
Ganga Pharmaceuticals Limited

Bharat Sharma
Managing Director
DIN : 00077026
Place: Virar, Palghar
Date : 2nd November, 2026

GANGA PHARMACEUTICALS LIMITED MUMBAI

GANGA PHARMACEUTICALS LTD

CIN: L99999MH1989PLC053392

Registered Office: Gangatat, Dhanvantari Marg, Gopcharpada, Virar (East), Palghar -401 305.
Phone No.9967840111 ; Website: www.ayurvedganga.com; Email id:ayurvedaganga@gmail.com

Statement of Un-Audited Assests and Liabilities as at 30th September 2026

Rs.in Lakhs

	Statement of Assets and Liabilities Particulars	As at (30-09-2026)	As at (31-03-2026)
A	EQUITY AND LIABILITIES		
	(1) Shareholders Funds:		
	(a) Share Capital	591.15	591.15
	(b) Reserve & Surplus	241.98	240.11
	(C)Money received against share warrants	-	-
	(2) Non-Current Liabilities		
	(a) Long-Term Borrowings	13.98	9.81
	(b) Deferred Tax Liabilities (Net)	0.06	0.32
	(c) Other Long Term Liabilities		-
	(d) Long Term Provisions		-
	(3) Current Liabilities		
	(a) Short-term borrowings	108.63	99.19
	(b) Trade payables		
	i) Total outsatnding dues of micro enterprises and small enterprises	-	(0.00)
	ii) Total outsatnding dues of creditors other then micro enterprises and small enterprises	13.68	11.80
	(c) Other current liabilities	9.50	9.52
	(d) Short-term provisions	4.02	3.03
	Total	983.01	964.93
B	ASSETS		
	(1) Non - Current assets		
	(a) Fixed Assets	62.60	64.57
	(b) Non-current investments	-	-
	(c) Deferred tax assets (net)	-	-
	(d) Long term loans and advances	-	-
	(e) Other Non-current assets	143.92	143.92
	(2) Current assets		
	(a) Current Investment		-
	(b) Inventories	116.38	116.52
	(c) Trade receivables	105.65	93.90
	(d) Cash and cash equivalents	2.17	5.82
	(e) Short-term loans and advances	316.87	292.53
	(f) Other current assets	235.41	247.68
	Total	983.01	964.93

For and on behalf of the Board of Directors of
Ganga Pharmaceuticals Limited

Bharat Sharma
Managing Director
DIN : 00077026
Place: Virar, Palghar
Date : 2nd November, 2026

GANGA PHARMACEUTICALS LIMITED MUMBAI

GANGA PHARMACEUTICALS LIMITED
(CIN: L99999MH1989PLC053392)
Cash Flow Statement for the half year ended 30th Septmber 2026.

	Half Year ended 30th September 2026 (Rs. In lakhs)	Half Year ended 30th September 2026 (Rs. In lakhs)	Year ended 31st March 2026 (Rs. In lakhs)	Year ended 31st March 2026 (Rs. In lakhs)
A. Cash flow from operating activities:				
Net profit before tax as per Profit and Loss Account.		2.52		12.93
Adjustment to reconcile profit before tax to net cash flows :				
Depreciation and amortisation expense	2.81		5.59	
Interest on advance & deposit recd	(13.64)		(27.91)	
Finance cost	5.53		12.31	
Profit on Sale of Shares	-		-	
		(5.30)		(10.01)
Operating profit before working capital changes		(2.79)		2.92
Movements in working capital:				
(Decrease) / Increase in trade payables	1.88		(15.96)	
(Decrease) / Increase in other liabilities	(0.02)		(2.61)	
(Decrease) / Increase in Short term borrowing	9.44		(19.75)	
(Decrease) / Increase in Short term Provision	0.99		1.55	
(Increase) / Decrease in trade receivables	(11.75)		(2.84)	
(Increase) / Decrease in other current assets	12.27		(53.97)	
(Increase) / Decrease in Short-term loans and advances	(24.34)		(39.08)	
(Increase) / Decrease in Inventories	0.13		1.70	
		(11.40)		(130.96)
Cash generated from operations		**(14.19)**		**(128.04)**
Taxes paid		(0.91)		(3.03)
Net cash from operating activities		**(15.09)**		**(131.07)**
B. Cash flow from investing activities:				
Purchase of fixed assets	(0.84)		(3.69)	
Profit on Sale of Shares	-		-	
Deposit made / matured during the year	-		0.15	
Investment made during the year	-		-	
Interest received	13.64		27.91	
Net cash used in investing activities		**12.80**		**24.37**

GANGA PHARMACEUTICALS LIMITED MUMBAI

GANGA PHARMACEUTICALS LIMITED
(CIN: L99999MH1989PLC053392)
Cash Flow Statement (Contd.)

	Year ended 30th September 2026 (Rs. In lakhs)	Year ended 30th September 2026 (Rs. In lakhs)	Year ended 31st March 2026 (Rs. In lakhs)	Year ended 31st March 2026 (Rs. In lakhs)
C. Cash flow from financing activities:				
Repayment of borrowings	4.17		(13.38)	
Proceeds from borrowings	-		-	
Proceeds from Issue of Shares and Warrants (net of Issue Expenses)			107.97	
Finance cost	(5.53)		(12.31)	
Net cash used in financing activities		**(1.36)**		**82.28**
Net increase / (Decrease) in cash and cash equivalents		(3.66)		(24.42)
Cash and cash equivalents as at the beginning of the year		5.82		30.24
Cash and cash equivalents as at the end of the year		**2.17**		**5.82**
Cash and cash equivalent comprises of :				
Cash in hand		1.96		1.38
Balance with banks		0.21		4.44
Total		**2.17**		**5.82**

Notes:

1 The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Notified Accounting Standard - 3 on Cash Flow Statements.
2 Figures in bracket indicate cash outgo.
3 Previous years' figures have been regrouped/rearranged to conform with current years' classifications.

As per our report of even date

For and on behalf of the board of directors of
Ganga Pharmaceutical Limited

GANGA PHARMACEUTICALS LIMITED MUMBAI

Bharat Sharma
Managing Director
DIN : 00077026
Place: Virar, Palghar
Date: 02/11/2026

Notes: -

1. The above results for the half year ended 30-09-2026 have been reviewed by the Audit Committee in their meeting held on 2nd November 2026 and approved by the Board of Directors in their meeting held on 2nd November 2026..
2. The Financial Results of the company have been prepared in accordance with Accounting Standards (AS) as prescribed under section 133 of the companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.
3. Revenues from Operations is net of trade Discounts/ Trade incentives.
4. In accordance with AS 17 on "Operating Segments', the company operated in one business segment viz. Ayurveda Business and hence segment information is not required to be furnished,
5. Figures of the corresponding previous period have been regrouped/rearranged wherever necessary to confirm to the classification of the current period.

For and on behalf of the Board of Directors

Ganga Pharmaceuticals Limited

GANGA PHARMACEUTICALS LIMITED MUMBAI

Bharat Sharma

Managing Director

DIN : 00077026

Place: Virar, Palghar

Date: 02nd November, 2026